Nanologica Q2 2023: Estimates largely maintained - Redeye

Redeye maintains its estimates with minor changes following Nanologica’s Q2 2023 report, on which we have a rather neutral take. Sales should start increasing from Q3 onwards, and we see the potential for an eventful H2 for Nanologica, which trades at a discount to our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/920890/nanologica-q2-2023-estimates-largely-maintained?utm_source=finwire&utm_medium=RSS